Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026
- Sponsor
- Rep. Hoyle, Val T. [D-OR-4]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Aug 13, 2026
Bottom line
This bill aims to reduce the cost of taxpayer-funded prescription drugs and biomedical products for U.S. consumers by linking their prices to international benchmarks and requiring reasonable pricing agreements for federally supported research.
What it actually does
This bill mandates that all federal agencies providing research funding for biomedical products or services require recipients to enter into reasonable pricing agreements with the Secretary of Health and Human Services. It specifically prohibits charging U.S. residents more than the median price in Canada and six other large, high-income OECD countries for these federally funded products. The bill also grants the Secretary authority to establish additional pricing requirements and outlines a public waiver process.
Proponents argue
Proponents argue this bill will ensure that the public benefits from taxpayer-funded research through affordable access to essential biomedical products, preventing pharmaceutical companies from charging exorbitant prices in the U.S. compared to other countries. They emphasize fairness and the return on public investment, asserting that public money should not lead to private windfalls at the expense of patient access.
Opponents contend
Opponents would likely argue that these pricing controls could stifle innovation by reducing the profitability and incentive for private companies to invest in the risky and expensive process of developing new drugs and therapies. They contend this could lead to fewer new treatments reaching patients, potentially causing drug shortages or discouraging market entry in the U.S. for federally funded innovations.
The bill is concise and can be read quickly, but its implications for drug pricing, innovation, and federal oversight are far-reaching and require careful consideration.
Section 2(a)
Requirement for Reasonable Price Agreements
This provision mandates that all federal agencies providing research funding (through grants, contracts, or other agreements) for biomedical products or services must include a requirement in their agreements that the price of any resulting product or service be 'reasonable,' as determined by the Secretary of Health and Human Services. This obligation also extends to any licenses of patent rights or regulatory test data derived from such federally funded research.
Supporters argue
Supporters argue this provision ensures that public investment in research translates into public benefit through affordable access to new treatments, preventing companies from monopolizing and price-gouging on innovations developed with taxpayer money.
Critics contend
Critics would contend that this requirement introduces uncertainty and reduces the commercial attractiveness of federally funded research, potentially deterring private investment and collaboration, thereby slowing down the development and availability of new biomedical products.
Tradeoffs
This provision balances the public interest in affordable access to drugs (return on investment) against the industry's need for profitability to incentivize innovation and R&D.
Section 2(b)
International Reference Pricing Standard
This subsection specifies that any 'reasonable pricing' formula must ensure that U.S. residents are not charged more for a federally funded biomedical product or service than the median price charged in Canada and six other large, high-income OECD countries. The Secretary can modify this reference price through regulation if deemed appropriate to protect U.S. residents from paying higher prices.
Section 2(c)
Secretary's Authority for Additional Pricing Requirements
This section grants the Secretary of Health and Human Services the authority to establish additional regulatory requirements to ensure reasonable pricing. These requirements must consider both the public interest in affordable innovations and the need for robust incentives for biomedical R&D. Possible mechanisms include lowering prices or shortening exclusivity periods when revenues exceed targets, lowering prices that exceed a standard of cost per health benefit, or lowering prices that create significant access barriers or fiscal burdens.
Section 2(d)
Public Interest Waiver for Reasonable Pricing Obligation
The Secretary may waive part or all of the reasonable pricing obligation if it is demonstrated to be in the public interest. Any such waiver requires public notice, an opportunity for comment (written and public hearing), and the publication of an economic analysis justifying the waiver before it takes effect.
Section 2(e)
Reporting and Public Availability of Cost and Revenue Data
This section requires manufacturers or companies commercializing federally funded biomedical products to report to the Secretary the costs of each clinical trial undertaken for regulatory approval, any federal subsidies received for those costs, and the annual revenues generated by the product, broken down by county of sale. The Secretary is mandated to make all such reports publicly available.
Section 2(f)
Preservation of Existing Pricing Requirements
This provision clarifies that the reasonable pricing requirements established by this Act are in addition to, and do not supersede, any other existing requirements to limit the price of biomedical products or services. This includes pricing standards in contracts or requirements under chapter 18 of title 35, U.S. Code (Bayh-Dole Act), which aims to make federally funded inventions available to the public on reasonable terms.
Section 2(g)
Definitions
This subsection defines key terms used throughout the Act, including 'biomedical product or service' (broadly covering drugs, vaccines, medical devices, diagnostics, etc.), 'medical device,' 'Secretary' (Secretary of Health and Human Services), and 'six reference countries' (six largest GDP, high-income OECD countries excluding Canada over the previous three years). These definitions clarify the scope and applicability of the bill's provisions.
This subsection clarifies that the new reasonable pricing requirements are in addition to, and do not replace, any existing requirements to limit the price of biomedical products or services, including those under the Bayh-Dole Act (Chapter 18 of title 35, U.S. Code).
Section 2(f)
Why it matters:This is standard legislative practice to ensure new laws integrate correctly with existing legal frameworks without inadvertently repealing or weakening prior protections.
Case for: Supporters would argue this ensures that the bill strengthens the existing framework for ensuring reasonable access to federally funded innovations, closing potential loopholes and preventing companies from claiming exemption from prior obligations.
Case against: Opponents might view this as further compounding regulatory burdens on companies, making it even less attractive to engage in federally funded research, without offering any offsetting relief from existing rules.
Estimated impact: Ensures that companies cannot use this new law to circumvent existing 'reasonable terms' requirements under the Bayh-Dole Act, potentially broadening the scope of price control mechanisms.
This definition specifies that the 'six reference countries' (used for international price referencing) are the six countries, excluding Canada, that over the previous three calendar years are OECD members, have the largest gross domestic products, and have a per capita income at least 50 percent of the average per capita income of the United States.
Section 2(g)(4)
Why it matters:This is a common legislative practice for defining terms, but the specific criteria are highly consequential for the bill's core mechanism and could be easily overlooked by a casual reader.
Case for: Proponents would argue that these specific criteria ensure that the reference countries are economically comparable to the U.S., providing a fair and relevant benchmark for drug pricing.
Case against: Critics might argue that the specific criteria could be manipulated or might not fully account for differences in healthcare systems, market sizes, or purchasing power, potentially leading to an artificially low benchmark that harms innovation.
Estimated impact: The precise selection criteria for these countries will directly determine the median international price, significantly influencing the upper limit of U.S. prices for affected biomedical products.